NasdaqGM:NTLABiotechs
FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang
FDA lifts clinical hold on Intellia Therapeutics' Phase 3 MAGNITUDE-2 trial of Nexiguran Ziclumeran (Nex-Z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
Regulators cleared trial resumption following agreement on study modifications and enhanced safety monitoring.
The decision affects Intellia Therapeutics' (NasdaqGM:NTLA) late stage gene editing pipeline and its progress in ATTRv-PN.
Intellia Therapeutics, traded as NasdaqGM:NTLA, is developing CRISPR based...